News & Events
Applied BioMath, LLC Announces Pharmacokinetic and Pharmacodynamic Modeling Collaboration with Compass Therapeutics
Applied BioMath, LLC Announces Quantitative Systems Pharmacology (QSP) Industry & Academia Symposium Speaker Lineup
Applied BioMath, LLC Announces Collaboration with Syntimmune for Pharmacokinetic and Pharmacodynamic Modeling in Clinical Program for Autoimmune Diseases
Applied BioMath, LLC awarded grant by National Institute on Aging of the NIH for the development of a systems pharmacology model in Alzheimer's Disease and Dementia
Using Systems Pharmacology Modeling Approaches to Guide Preclinical Animal Studies
John M. Burke, Applied BioMath
Asawari Samant, MathWorks
Inventing and developing safe and efficacious drugs is a difficult task, especially for co-modulation proteins that regulate the immune response for chronic autoimmune diseases. For example, there must be adequate target coverage to dampen the immune response, but not so much as to essentially shut off the immune system. The development of a bispecific biologic that targets two different co-modulation proteins expressed on cells is even more complex. In this webinar, we apply systems pharmacology techniques to predict the therapeutic window in cyno monkeys for this bispecific biologic.
In the second half of the webinar, we will demonstrate how SimBiology can be used to implement systems pharmacology approaches within the context of this bispecific biologic example.
- Building and characterizing a mechanistic model for bispecific biologics
- Exploring dosing strategies to achieve response in the therapeutic window
About the Presenters:
John M. Burke, PhD, is President, CEO and Co-founder of Applied BioMath, LLC, a Systems Biology and Pharmacology company. Dr. Burke’s BS and MS are in Applied Mathematics, University of Massachusetts, Lowell. His PhD degree is in Applied Mathematics, Arizona State University, where he studied dynamical systems, singular perturbation theory, and control of signal transduction networks and protein expression. Prior to Applied BioMath, Dr. Burke joined Boehringer Ingelheim (BI), as Global Head of Systems Biology, where he started, developed and managed the Systems Biology and Pharmacology group, portfolio, strategy and tactics. At BI, his group supported over 100 projects in five years, and over 11 transitions into Development or Clinical Trials. Prior to Boehringer Ingelheim, he was a Sr. Fellow in Douglas A. Lauffenburger’s lab, Biological Engineering Department, MIT; Co-Scientific Director of the Cell Decision Processes Center, Systems Biology Department, Harvard Medical School; then Merrimack Pharmaceuticals.
Asawari Samant is a Senior Application Engineer at MathWorks. She has a B.S. and M.S. in chemical engineering. At MathWorks, she primarily supports the pharmaceutical and biotechnology industry, and the computational biology sector.Start Date: Feb 3, 2015 08:00
Quantitative systems pharmacology modeling (QSPM) approach provides biological insights and predicts optimal drug properties for dual targeting approaches for two immuno-oncology therapeutics
Biotech and Pharma are increasingly using quantitative systems pharmacology modeling (QSPM) approaches to help answer complex, critical Go/No-go decisions in R&D. Dr. John Burke will discuss the: • Value of QSP approaches • A QSP industry case study The case study entails developing and interrogating a QSPM of PD-1 and TIM-3. The QSPM provided: • Biological insights by predicting why dosing regimens are quite similar for two therapeutics targeting PD-1 that have affinities that differ by several orders of magnitude • Best-in-class profile predictions for PD-1 and TIM-3 dual antagonists This webinar is ideal for scientists in R&D who want to learn more about how to leverage QSPM to shorten timelines, lower cost, and increase the likelihood of developing best-in-class drugs. Speaker Info: John M. Burke, PhD Co-Founder, President, and CEO email@example.com Prior to co-founding Applied BioMath, Dr. Burke was an Associate Director, Head of Systems Biology at Boehringer Ingelheim where he started, developed and managed the Systems Biology group, portfolio, and strategy. Prior to Boehringer Ingelheim, Dr. Burke was at Merrimack Pharmaceuticals, Co-Scientific Director of the Cell Decision Processes Center, Systems Biology Department, HMS, and was a Sr. Postdoctoral Fellow in Douglas A. Lauffenburger’s lab, Biological Engineering Department, MIT. Dr. Burke holds a PhD degree in Applied Mathematics from Arizona State University.Start Date: Apr 5, 2016 12:45